Lucentis (ranibizumab) / Roche, Novartis 
Welcome,         Profile    Billing    Logout  
 172 Diseases   135 Trials   135 Trials   7089 News 


«12...5556575859606162636465...7475»
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Enrollment closed:  CAN-TREAT: Canadian Treat and Extend Analysis Trial With Ranibizumab (clinicaltrials.gov) -  Feb 15, 2017   
    P=N/A,  N=580, Active, not recruiting, 
    Trial primary completion date: Dec 2016 --> Apr 2018 Recruiting --> Active, not recruiting
  • ||||||||||  Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
    New trial:  30g vs 33g Needle for Intravitreal Injections (clinicaltrials.gov) -  Jan 30, 2017   
    P=N/A,  N=100, Recruiting, 
  • ||||||||||  Izervay (avacincaptad pegol intravitreal solution) / Astellas
    Phase classification:  A Study to Establish the Safety and Tolerability of Zimura (clinicaltrials.gov) -  Jan 23, 2017   
    P2a,  N=4, Completed, 
    Not yet recruiting --> Recruiting | Initiation date: Jun 2016 --> Jan 2017 Phase classification: P2 --> P2a
  • ||||||||||  Fumena (vorolanib) / Tyrogenex
    Enrollment closed, Monotherapy, Head-to-Head:  X-82 to Treat Age-related Macular Degeneration (clinicaltrials.gov) -  Jan 13, 2017   
    P2,  N=132, Active, not recruiting, 
    Terminated --> Suspended | Trial primary completion date: May 2016 --> Feb 2016 Recruiting --> Active, not recruiting
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Trial completion, Monotherapy:  Macular EpiRetinal Brachytherapy Versus Lucentis (clinicaltrials.gov) -  Dec 22, 2016   
    P4,  N=363, Completed, 
    Not yet recruiting --> Recruiting Active, not recruiting --> Completed
  • ||||||||||  Fovista (pegpleranib) / Roche, Astellas
    Trial termination, Combination therapy, Monotherapy:  A Phase 3 Safety and Efficacy Study of Fovista (clinicaltrials.gov) -  Dec 21, 2016   
    P3,  N=619, Terminated, 
    Active, not recruiting --> Completed Active, not recruiting --> Terminated
  • ||||||||||  Fovista (pegpleranib) / Roche, Astellas
    Trial termination, Combination therapy, Monotherapy:  A Phase 3 Safety and Efficacy Study of Fovista (clinicaltrials.gov) -  Dec 21, 2016   
    P3,  N=627, Terminated, 
    Active, not recruiting --> Terminated Active, not recruiting --> Terminated
  • ||||||||||  Fovista (pegpleranib) / Roche, Astellas
    Trial termination, Combination therapy:  Phase 2A Open Label Safety Study of Fovista (clinicaltrials.gov) -  Dec 21, 2016   
    P2a,  N=101, Terminated, 
    Active, not recruiting --> Terminated Active, not recruiting --> Terminated
  • ||||||||||  Fovista (pegpleranib) / Roche, Astellas
    Phase classification, Trial termination, Combination therapy:  A 24 Month Phase 2a Open Label, Randomized Study of Avastin (clinicaltrials.gov) -  Dec 21, 2016   
    P2a,  N=64, Terminated, 
    Active, not recruiting --> Terminated Phase classification: P2 --> P2a | Active, not recruiting --> Terminated
  • ||||||||||  Fovista (pegpleranib) / Roche, Astellas
    Trial primary completion date, Combination therapy, Monotherapy:  A Phase 3 Safety and Efficacy Study of Fovista (clinicaltrials.gov) -  Dec 14, 2016   
    P3,  N=627, Active, not recruiting, 
    Recruiting --> Active, not recruiting Trial primary completion date: Jul 2016 --> Dec 2016
  • ||||||||||  Fovista (pegpleranib) / Roche, Astellas
    Enrollment closed, Trial primary completion date, Combination therapy, Monotherapy:  A Phase 3 Safety and Efficacy Study of Fovista (clinicaltrials.gov) -  Dec 14, 2016   
    P3,  N=619, Active, not recruiting, 
    Trial primary completion date: Jul 2016 --> Dec 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2016 --> Dec 2016
  • ||||||||||  Fumena (vorolanib) / Tyrogenex
    Trial primary completion date, Monotherapy, Head-to-Head:  X-82 to Treat Age-related Macular Degeneration (clinicaltrials.gov) -  Nov 16, 2016   
    P2,  N=132, Recruiting, 
    Recruiting --> Active, not recruiting | Initiation date: Jun 2014 --> Oct 2014 Trial primary completion date: Oct 2016 --> Jan 2017
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Biomarker, Trial primary completion date:  Genetics in Non-response to Anti-VEGF Treatment in Exudative AMD (clinicaltrials.gov) -  Oct 26, 2016   
    P4,  N=110, Active, not recruiting, 
    N=40 --> 0 | Suspended --> Withdrawn Trial primary completion date: Dec 2016 --> Dec 2017
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Enrollment closed, Enrollment change, Trial primary completion date:  PROTECT: Prophylactic Ranibizumab for Exudative Age-Related Macular Degeneration (clinicaltrials.gov) -  Oct 19, 2016   
    P1/2,  N=4, Active, not recruiting, 
    Trial primary completion date: Apr 2018 --> Mar 2019 Recruiting --> Active, not recruiting | N=88 --> 4 | Trial primary completion date: Nov 2017 --> Jul 2017
  • ||||||||||  hI-con1 (ICON-1) / Endpoint Health
    Trial completion:  EMERGE: Study Evaluating Intravitreal hI-con1 (clinicaltrials.gov) -  Oct 12, 2016   
    P2,  N=88, Completed, 
    Initiation date: Apr 2016 --> Nov 2016 Active, not recruiting --> Completed
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Trial primary completion date:  Noctura400 Treatment for Diabetic Retinopathy (CANDLE) (clinicaltrials.gov) -  Oct 11, 2016   
    P=N/A,  N=240, Recruiting, 
    Active, not recruiting --> Completed Trial primary completion date: Dec 2016 --> Dec 2017
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Trial completion:  Dosing Study of Ranibizumab for Diabetic Retinal and Macular Edema (clinicaltrials.gov) -  Oct 5, 2016   
    P2,  N=20, Completed, 
    Trial primary completion date: Dec 2016 --> Dec 2017 Active, not recruiting --> Completed